

Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload

Arnaud Charles Tiberghien, Jean-Noel Levy, Luke A. Masterson, Neki V. Patel, Lauren R. Adams, Simon Corbett, David G. Williams, John A. Hartley, and Philip W. Howard

ACS Med. Chem. Lett., **Just Accepted Manuscript** • DOI: 10.1021/acsmedchemlett.6b00062 • Publication Date (Web): 24 May 2016

Downloaded from <http://pubs.acs.org> on May 30, 2016

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.




Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload

Arnaud C. Tiberghien*, Jean-Noel Levy†, Luke A. Masterson, Neki V. Patel, Lauren R. Adams, Simon Corbett, David G. Williams, John A. Hartley, Philip W. Howard*

Spirogen, QMB Innovation Centre, 42 New Road, E1 2AX, London

Tesirine, Antibody-drug conjugates, Talirine, SG3249, Rova-T

ABSTRACT: Pyrrolobenzodiazepine dimers are an emerging class of warhead in the field of antibody-drug conjugates (ADCs). Tesirine (SG3249) was designed to combine potent anti-tumor activity with desirable physico-chemical properties such as favorable hydrophobicity, and improved conjugation characteristics. One of the reactive imines was capped with a cathepsin B-cleavable valine-alanine linker. A robust synthetic route was developed to allow the production of tesirine on clinical scale, employing a flexible, convergent strategy. Tesirine was evaluated *in vitro* both in stochastic and engineered ADC constructs, and was confirmed as a potent and versatile payload. The conjugation of tesirine to anti-DLL3 rovalpituzumab has resulted in rovalpituzumab-tesirine (Rova-T), currently under evaluation for the treatment of small cell lung cancer.



Since their discovery in 1963,^{1, 2} pyrrolobenzodiazepines (PBDs) have been studied for their anti-tumor properties. Both naturally occurring monomer anthramycin, and synthetic dimer SG2000 have undergone clinical evaluation as stand-alone agents.³ Until recently,⁴ however, this more potent class of molecule remained under-exploited as a source of warhead for antibody-drug conjugates (ADCs).

Antibody-drug conjugates combine the potency of a cytotoxic warhead with the selectivity of an antibody to enable targeted killing of tumor cells. Most ADCs currently in clinical evaluation are based on anti-mitotic warheads such as auristatin and maytansine.⁵

Given their potency and mode of action as sequence-selective cross-linking agents, we hypothesized the ADC field would benefit from the employment of PBDs as a new class of warhead. A collaboration between Spirogen and Seattle Genetics led to the development of SGN-CD33A, an ADC under clinical investigation for the treatment of acute myeloid leukemia, featuring the PBD payload SGD-1910 or talirine.^{6, 7} We aimed to improve on the design of SGD-1910 by lowering hydrophobicity whilst maintaining potency. (**Figure 1**)




Figure 1. Structures of SG2202 and ADC warhead SG3199. LogD values calculated at pH 7.4. Structures of payloads (drug-linker) SG3249 (tesirine), and SGD-1910 (talirine). Red coding denotes released warhead. Conventional ring numbering shown on SG3199.

We also investigated trapping one of the reactive imine moieties in its carbinolamine form by incorporating the N10 nitrogen as part of a cathepsin B-cleavable valine-alanine carbamate prodrug linker.⁸ Finally, a discrete PEG₈ spacer was inserted to further enhance the solubility properties of the molecule. This design resulted in the payload SG3249 (tesirine).

The warhead component of tesirine, SG3199 (**Figure 1**), was based on rational design principles. The C2 aryls, responsible both for the high potency and poor aqueous solubility of SG2202 and analogues^{9,10}, were replaced with simpler methyl groups. The expected drop in potency was offset by the introduction of a 5-carbon tether between the two monomers. Both 3-carbon and 5-carbon tether linked PBDs are isohelical with the DNA helix, but the 5-carbon tether is more flexible and has greater opportunities for contact with the minor groove.^{11,12} SG3199 was tested in a panel of cancer cell lines and retained picomolar activity *in vitro*. (**Table 1**).


Table 1. *In vitro* activity of warhead SG3199.

Compound	Cell line IC ₅₀			
	K562	NCIN87	BT474	SKBR3
SG3199	150 pM	20 pM	1 nM	320 pM

IC₅₀ values (mean of three independent experiments) were determined using CellTiter96 (MTS) following 96h incubation.

Rather than following a linear route as used in the synthesis of SG2202 or SG2000 (SJC-136),¹³ we decided to follow a convergent synthetic route, allowing both the left-hand (linker) and right-hand (imine) sides of the unsymmetrical dimer to be made in parallel, followed by late-stage dimerization. Monomeric routes have been developed previously by Howard *et al.*,¹² and Kamal *et al.*¹⁴ Recently Kolakowski *et al.*¹⁵ have reported the application of a convergent strategy to the synthesis of an unsymmetrical C2-aryl substituted PBD. In contrast to these other strategies, we selected *N*-alloc and *O*-TBS as the N10-imine and C11-hydroxy protecting groups for mild and efficient deprotection in the final stages of the synthesis. Both groups are resistant to base and mild acid, but can be orthogonally removed when required.

Scheme 1: Synthesis and coupling of A and C rings




Reagents and conditions: (a) HNO₃, 12 °C, 95%, (b) TFA, 85 °C, 50%, (c) TIPSCl, imidazole, 100 °C, 88%, (d) NaClO₂, NaH₂PO₄, H₂O₂, THF, rt, -78 °C to rt, 100%, (e) DCC, HOBt, Et₃N, DCM, -10 °C to rt, 90%, (f) TEMPO, TCCA, DCM, 100%.

Controlled nitration of benzylvanillin afforded intermediate **2** (**Scheme 1**).¹⁶ This was followed by an exchange of protecting

groups at the phenolic position. TIPS was selected for its relatively high resistance to acid and base, with the option of selective phenolic silyl deprotection in the presence of aliphatic silyl ethers. Clean and efficient Pinnick oxidation of benzaldehyde **4** gave acid **5**. Amide bond formation with hydroxyproline derivative **6**¹¹ gave alcohol **7** (see supplementary information), which was oxidized using the reactive TEMPO/TCCA combination. Thermodynamic treatment of compound **8**^{17,18} with triflic anhydride gave triflate **9** in 78% yield (**Scheme 2**). This was followed by a *sp*²-*sp*³ Suzuki coupling to install a methyl group at the C2 position. Activated conditions developed by Mu and Gibbs,¹⁹ employing silver oxide and triphenylarsine, were required for efficient coupling. Optimization of the reaction conditions was necessary to avoid competing triflate reduction; the resulting impurity **10** having similar chromatographic retention properties to the desired compound **11**. When the same conditions were investigated with homologous ethyl boronic acid, a much larger proportion of reduced material **10** was found to contaminate the mixture. The nitro group was reduced with zinc and dilute formic acid in ethanol. These conditions were mild enough to leave both the primary TBS ether and the internal unsaturation intact.

Scheme 2: Synthesis of monomeric phenol **20** and **21**




Reagents and conditions: (a) Tf₂O, 2,6-lutidine, DCM, -45 °C, 78%, (b) MeB(OH)₂, Ag₂O, AsPh₃, Pd(PhCN)₂Cl₂, 70 °C, 70% (c) Zn (30 eq.), HCOOH/ EtOH 5/95, 30 °C, 80% (d) Alloc-Cl, pyridine, DCM, -78 °C to rt, 100% (e) triphosgene, Et₃N, THF, 5 °C, then Alloc-Val-Ala-PAB-OH, Et₃N, THF, 40 °C, 50%, (f) AcOH/MeOH/THF/water 7/1/1/2, rt, 71%, **15**, 80%, **16**, (g) DMSO, (COCl)₂, Et₃N, DCM, -78 °C to rt, 66%, **17**, 60%, **18** (h) TBSOTf, 2,6-lutidine, DCM, 0 °C, 85%, **19**, 65%, **20**, (i) LiOAc, DMF/water, 95/5, rt, 100%, **21**, 100%, **22**.

At this key juncture in the synthesis, carbamates **13** and **14** were formed from **12**, either by treatment with alloc chloroformate, or through the initial formation of an

isocyanate²⁰ followed by addition of alloc-Val-Ala-*para*-aminobenzylalcohol.²¹ The two resulting monomeric intermediates **13** and **14** were subjected to the same sequence of reactions beginning with mild acid hydrolysis of the primary TBS and ring-closing oxidation under Swern conditions. Protection of the 11-hydroxy group is critical at this point to allow further chemistry to proceed under basic or acidic conditions whilst preserving the 11*a* stereochemistry.²² The use of highly reactive TBS triflate²³ was necessary to achieve efficient secondary alcohol protection. Finally, mild and orthogonal deprotection of the phenolic TIPS in the presence of aliphatic TBS was achieved with LiOAc in wet DMF²⁴ to provide both the right-hand and left-hand side monomers **21** and **22**.

Williamson ether chemistry, proceeding *via* iodopentane derivatization of alloc-protected monomer **21** and subsequent reaction with monomer **22**, provided dimer **24** in 86% yield (Scheme 3). Removal of 11-hydroxy TBS with TBAF resulted in partial racemization at C11*a*. (Detectable by LC and optical rotation analyses of SG3249: Figure 2, Table 2). Buffering the fluoride solution with acetic acid was found to prevent racemisation.^{25, 26}

Scheme 3: Final steps, synthesis of SG3249 (tesirine)



Reagents and conditions: (a) 1,5-Diiodopentane, K₂CO₃, acetone, 60 °C, 90%, (b) **22**, K₂CO₃, acetone, 65 °C, 86%, (c) TBAF/AcOH, THF, rt, 80%, (d) Pd(PPh₃)₄, pyrrolidine, DCM, rt, 100%, (e) Mal-dPEG₈-acid, EDCl, DCM, rt, 73%.




Figure 2. UPLC of SG3249: a) unbuffered TBAF used in Scheme 3, step c; b) buffered TBAF. Ace Excel 2 C18-AR (2 μ m, 3.0 mm x 100 mm), 40 °C, 20 mM ammonium formate (pH = 4) /acetonitrile, 25/75 to 55/45 over 30 min, 0.6 mL/min. Peaks i and ii in a) Diastereoisomers of SG3249. Peak i in b): pure SG3249.

Table 2. SG3249 optical rotation

SG3249 Batch	Optical rotation	TBS Cleavage
Unbuffered	+118° (c = 0.43)	TBAF
Buffered	+262° (c = 0.56)	TBAF/AcOH 1/1

SG3249 batches made with either an unbuffered or buffered TBS cleavage step (Scheme 3, step c). Measurement in chloroform at 20 °C.

Both alloc groups were rapidly and efficiently removed with Pd(0) and pyrrolidine as a an allyl scavenger²⁷, in a Tsuji-Trost reaction.²⁸ The absence of pyrrolidine scavenging during the deprotection resulted in the formation of N10-allylated impurities. The resulting compound **26** was immediately used in the next step without further purification. Traces of palladium were effectively removed, both by chromatography of the payload SG3249, and purification of the final ADC. Interestingly, reversible macrocycle **27** was found to form upon standing in solution with the valine amino group adding across the PBD imine of **26** (NMR and structure in supporting information). However, we found that both **26** and **27** could be fully consumed under final coupling conditions with EDCI and Mal-dPEG₈-Acid to form SG3249 in 73% yield. The overall yield for the synthesis was 0.54% from benzylvanillin over 30 steps.

Despite its length, the synthetic route described has shown a number of advantages such as robustness on scale, modularity of monomeric building blocks, as well as mild and efficient final steps. The same route was used to provide clinical grade material and is continuously being optimized.

To explore its potential as a payload, SG3249 was conjugated to trastuzumab (Herceptin®) in a stochastic fashion, and to an engineered version featuring two reactive cysteine positions (site-specific Herceptin-SG3249) (Table 3). Finally, SG3249 was conjugated to a control, non-binding, engineered antibody. SG3249 conjugation to all antibodies was highly efficient, as illustrated by a readily tuneable stochastic ADC average drug-

to-antibody ratio (DAR of 2.5 in this instance; the DAR can be tuned by varying the amount of TCEP reducing agent) and site-specific ADC DAR of 1.8 (90% conjugation efficiency). SG3249 was found readily soluble in the 10% DMSO aqueous conjugation buffer (50 mg/L, see supporting information, solubility limit not determined). In contrast, SGD-1910, bearing C2-aryls and devoid of PEG linker, had to be conjugated in 50% propylene glycol⁶. SG3249 low hydrophobicity ($\log D_{7.4} = 2.11$) resulted in low levels of aggregation (usually < 5%). As a result, the conjugation process reproducibly delivered high monomeric purity ADCs in high yields, on microgram to gram scale.

Table 3. ADC conjugation properties and GI50 in SKBR3.

ADC	DAR	Yield (%)	Process aggregation (% dimer)	GI50 (ng/mL)
Her-SG3249	2.51	86	2.81	1.74
Site-specific Her-SG3249	1.81	89	3.93	2.62
IgG control mAb-SG3249	1.79	87	3.11	1101

DAR assessed by RP-HPLC. Process aggregation assessed by SEC. GI50 in SKBR3 (Figure 3). Yields calculated based on concentration measurements.

Gratifyingly, both the stochastic and site-specific Herceptin-SG3249 ADCs were active in the ng/mL range against HER2-expressing human breast cancer cell line SKBR3 (Figure 3, Table 3). Both HER2-targeted ADCs were greater than two orders of magnitude more potent than the control non-HER2-binding ADC, indicating target specificity. The residual activity of the non-targeted control ADC is likely due to non-specific uptake (such as clathrin-mediated endocytosis) at high assay concentrations. Linker stability studies will be undertaken to further address this point and will appear in subsequent publications. Preliminary evidence tends to show good linker stability when SG3249 is conjugated at buried positions within the antibody structure.




Figure 3. Growth inhibition curves in human SKBR3 cells for SG3249 ADCs.

In conclusion, SG3249 possesses an attractive set of properties: potency, synthetic route scalability, low hydrophobicity contributing to low aggregation, cathepsin B-cleavable linker, and efficient maleimide conjugation.

The *in vivo* evaluation of SG3249 ADCs will be described elsewhere. SG3249 has been conjugated with rovalpituzumab. The resulting ADC has recently successfully completed a phase I clinical trial for the treatment of small cell lung cancer.^{29, 30} Initial data from rovalpituzumab-tesirine (Rova-T) is encouraging,³¹ and should pave the way for a phase II trial. In addition, SG3249 forms the payload component of ADCT-301, which is currently in a phase I trial for CD25-positive hematological malignancies.^{32, 33}

The pyrrolobenzodiazepine dimer class of warheads is finding increasing utility in the ADC arena based on their versatility and complementary mode of action to anti-mitotic tubulin binders.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website.

Detailed experimental procedures with analytical data for all intermediates. Graphical ¹H NMR and ¹³C NMR for compounds of interest. Interpreted, graphical ¹H NMR for SG3249 and macrocycle 27. (PDF)

AUTHOR INFORMATION

Corresponding Authors

AT, e-mail: uberghiena@medimmune.com

PH, e-mail: philip.howard@spirogen.com

Present Addresses

†Former employee of Spirogen. Present address: Stemcentrx, Inc., 450 East Jamie Court, South San Francisco, CA 94080

Funding

This study was supported by Spirogen, a member of AstraZeneca group of companies.

Notes

AT, LM, NP, LA, DW, JH and PH are Spirogen employees. JL is a Stemcentrx employee.

ACKNOWLEDGMENT

The authors wish to thank Stephen Gregson for editing the manuscript and providing valuable scientific feedback. The authors also wish to thank Krisztina Radi for providing SG3249 UPLC data, and Gyoung Dong Kang and Conor Barry for providing HRMS data. Christian Noti and colleagues are acknowledged for their NMR work on SG3249 and macrocycle 27. Michael Torgov is acknowledged for his contribution to the development of SG3249 analytical conditions.

ABBREVIATIONS

ADC, antibody drug conjugate; PBD, pyrrolobenzodiazepine; DLL3, Delta-like 3; Her, Herceptin; HER2, human epidermal growth factor receptor 2; PABC; *para*-aminobenzylcarbamate; DAR, drug-to-antibody ratio; TBAF, Tetrabutylammonium fluoride; DCM, dichloromethane; Mal, Maleimide; dPEG, discrete poly-ethylene glycol; EDCI, N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride; TFA, Trifluoroacetic acid; TIPS, Triisopropyl silyl; DCC, Dicyclohexylcarbodiimide; HOBt, 1-

Hydroxybenzotriazole; TEMPO, 2,2,6,6-Tetramethylpiperidine 1-oxyl; TCCA, Trichloroisocyanuric acid; TBS, *tert*-Butyldimethylsilyl; alloc, allyloxycarbonyl.

REFERENCES

1. Leimgruber, W.; Stefanovic, V.; Schenker, F.; Karr, A.; Berger, J., Isolation and characterization of anthramycin, a new antitumor antibiotic. *J. Am. Chem. Soc.* **1965**, 87, (24), 5791-3.
2. Tendler, M. D.; Korman, S., 'Refuin': A non-cytotoxic carcinostatic compound proliferated by a thermophilic actinomycete. *Nature* **1963**, 199, 501.
3. Hartley, J. A., The development of pyrrolobenzodiazepines as antitumour agents. *Expert Opin. Investig. Drugs* **2011**, 20, (6), 733-44.
4. Kung Sutherland, M. S.; Walter, R. B.; Jeffrey, S. C.; Burke, P. J.; Yu, C.; Kostner, H.; Stone, I.; Ryan, M. C.; Sussman, D.; Lyon, R. P.; Zeng, W.; Harrington, K. H.; Klussman, K.; Westendorf, L.; Meyer, D.; Bernstein, I. D.; Senter, P. D.; Benjamin, D. R.; Drachman, J. G.; McEarchern, J. A., SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. *Blood* **2013**, 122, (8), 1455-63.
5. Chari, R. V.; Miller, M. L.; Widdison, W. C., Antibody-drug conjugates: an emerging concept in cancer therapy. *Angew. Chem. Int. Ed. Engl.* **2014**, 53, (15), 3796-827.
6. Jeffrey, S. C.; Burke, P. J.; Lyon, R. P.; Meyer, D. W.; Sussman, D.; Anderson, M.; Hunter, J. H.; Leiske, C. I.; Miyamoto, J. B.; Nicholas, N. D.; Okeley, N. M.; Sanderson, R. J.; Stone, I. J.; Zeng, W.; Gregson, S. J.; Masterson, L.; Tiberghien, A. C.; Howard, P. W.; Thurston, D. E.; Law, C. L.; Senter, P. D., A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. *Bioconjug. Chem.* **2013**, 24, (7), 1256-63.
7. A safety study of SGN-CD33A in AML patients. <https://www.clinicaltrials.gov/ct2/show/NCT01902329>
8. Jeffrey, S. C.; Nguyen, M. T.; Andreyka, J. B.; Meyer, D. L.; Doronina, S. O.; Senter, P. D., Dipeptide-based highly potent doxorubicin antibody conjugates. *Bioorg. Med. Chem. Lett.* **2006**, 16, (2), 358-362.
9. Howard, P. W.; Chen, Z.; Gregson, S. J.; Masterson, L. A.; Tiberghien, A. C.; Cooper, N.; Fang, M.; Coffils, M. J.; Klee, S.; Hartley, J. A.; Thurston, D. E., Synthesis of a novel C2/C2'-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate. *Bioorg. Med. Chem. Lett.* **2009**, 19, (22), 6463-6.
10. Hartley, J. A.; Hamaguchi, A.; Coffils, M.; Martin, C. R. H.; Suggitt, M.; Chen, Z.; Gregson, S. J.; Masterson, L. A.; Tiberghien, A. C.; Hartley, J. M.; Pepper, C.; Lin, T. T.; Fegan, C.; Thurston, D. E.; Howard, P. W., SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity. *Cancer Research* **2010**, 70, (17), 6849-6858.
11. Gregson, S. J.; Howard, P. W.; Gullick, D. R.; Hamaguchi, A.; Corcoran, K. E.; Brooks, N. A.; Hartley, J. A.; Jenkins, T. C.; Patel, S.; Guille, M. J.; Thurston, D. E., Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. *J. Med. Chem.* **2004**, 47, (5), 1161-74.
12. Howard, P. W.; Kang, G.-D. Preparation, DNA crosslinking reactivity and antiproliferative activity of pyrrolobenzodiazepine dimers. WO2005085259A2, 2005.
13. Gregson, S. J.; Howard, P. W.; Hartley, J. A.; Brooks, N. A.; Adams, L. J.; Jenkins, T. C.; Kelland, L. R.; Thurston, D. E., Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. *J. Med. Chem.* **2001**, 44, (5), 737-48.
14. Kamal, A.; Ramesh, G.; Laxman, N.; Ramulu, P.; Srinivas, O.; Neelima, K.; Kondapi, A. K.; Sreenu, V. B.; Nagarajaram, H. A., Design, synthesis, and evaluation of new non-cross-Linking pyrrolobenzodiazepine dimers with efficient DNA binding ability and potent antitumor activity. *J. Med. Chem.* **2002**, 45, (21), 4679-4688.
15. Kolakowski, R. V.; Young, T. D.; Howard, P. W.; Jeffrey, S. C.; Senter, P. D., Synthesis of a C2-aryl-pyrrolo[2,1-c][1,4]benzodiazepine monomer enabling the convergent construction of symmetrical and non-symmetrical dimeric analogs. *Tetrahedron Letters* **2015**, 56, (30), 4512-4515.
16. Althuis, T. H.; Hess, H. J., Synthesis and identification of the major metabolites of prazosin formed in dog and rat. *J. Med. Chem.* **1977**, 20, (1), 146-9.
17. Howard, P. W. Preparation of pyrrolobenzodiazepine dimers and their conjugates with cell binding agents, especially pyrrolobenzodiazepine dimer drug linker antibody conjugates containing dipeptide linkers, and their use for treating proliferative diseases, particularly cancer. WO2014057074A1.
18. Howard, P. W.; Tiberghien, A. Process for the preparation of intermediates useful for the synthesis of pyrrolobenzodiazepine dimers. WO2013053872A1.
19. Mu, Y.; Gibbs, R. A., Coupling of isoprenoid triflates with organoboron nucleophiles: Synthesis of all-trans-geranylgeraniol. *Tetrahedron Letters* **1995**, 36, (32), 5669-5672.
20. Masterson, L. A.; Spanswick, V. J.; Hartley, J. A.; Begent, R. H.; Howard, P. W.; Thurston, D. E., Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy. *Bioorg. Med. Chem. Lett.* **2006**, 16, (2), 252-6.
21. Howard, P. W.; Masterson, L.; Tiberghien, A.; Flygare, J. A.; Gunzner, J. L.; Polakis, P.; Polson, A.; Raab, H. E.; Spencer, S. D. Preparation of pyrrolobenzodiazepine dimers and conjugates, especially pyrrolobenzodiazepine dimer drug linker conjugates containing peptide linkers, and their use for treating proliferative diseases including cancer. WO2011130598A1.
22. Wells, G.; Martin, C. R.; Howard, P. W.; Sands, Z. A.; Laughton, C. A.; Tiberghien, A.; Woo, C. K.; Masterson, L. A.; Stephenson, M. J.; Hartley, J. A.; Jenkins, T. C.; Shnyder, S. D.; Loadman, P. M.; Waring, M. J.; Thurston, D. E., Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates. *J. Med. Chem.* **2006**, 49, (18), 5442-61.
23. Corey, E. J.; Cho, H.; Rucker, C.; Hua, D. H., Studies with trialkylsilyltriflates: new syntheses and applications. *Tetrahedron Letters* **1981**, 22, (36), 3455-3458.
24. Wang, B.; Sun, H. X.; Sun, Z. H., LiOAc-catalyzed chemoselective deprotection of aryl silyl ethers under mild conditions. *J. Org. Chem.* **2009**, 74, (4), 1781-4.
25. Kocienski, P. J., *Protecting Groups*. 3rd ed.; Thieme: 2005; p 208.
26. Terauchi, T.; Tanaka, T.; Terauchi, T.; Morita, M.; Kimijima, K.; Sato, I.; Shoji, W.; Nakamura, Y.; Tsukada, T.; Tsunoda, T.; Hayashi, G.; Kanoh, N.; Nakata, M., Formal total synthesis of altohyrtin C (spongistatin 2). Part 2: Construction of fully elaborated ABCD and EF fragments. *Tetrahedron Lett.* **2003**, 44, (42), 7747-7751.
27. Deziel, R., Mild palladium (O)-catalyzed deprotection of allyl esters. A useful application in the synthesis of carbapenems and other B-lactam derivatives. *Tetrahedron Letters* **1987**, 28, (38), 4371-4372.
28. Kurti, L.; Czako, B., *Strategic Applications of Named Reactions in Organic Synthesis*. Elsevier Academic Press: 2005; p 458-9.
29. SC16LD6.5 in recurrent small cell lung cancer. <https://clinicaltrials.gov/ct2/show/NCT01901653>
30. Saunders, L. R.; Bankovich, A. J.; Anderson, W. C.; Aujay, M. A.; Bheddah, S.; Black, K.; Desai, R.; Escarpe, P. A.; Hampl, J.; Laysang, A.; Liu, D.; Lopez-Molina, J.; Milton, M.; Park, A.; Pysz, M. A.; Shao, H.; Slingerland, B.; Torgov, M.; Williams, S. A.; Foord, O.; Howard, P.; Jassem, J.; Badzio, A.; Czapiewski, P.; Harpole, D. H.; Dowlati, A.; Massion, P. P.; Travis, W. D.; Pietanza, M. C.; Poirier, J. T.; Rudin, C. M.; Stull, R. A.; Dylla, S. J., A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. *Sci. Transl. Med.* **2015**, 7, (302), 302ra136.
31. Pietanza M.C.; Spigel D.; Bauer T.M.; Ready N.E.; Glisson B.S.; Morgensztern D.; Robert F.; Salgia R.; Kochendorfer M.; Patel M.; Strickland D.K.; Govindan R.; Burris H.A.; Rudin C.M.; Dylla S., Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). In *European Cancer Congress*, 2015.
32. Study of ADCT-301 in patients with relapsed or refractory Hodgkin and non-Hodgkin lymphoma. <https://www.clinicaltrials.gov/ct2/show/NCT02432235>
33. Flynn M.; Berkel P.; Zammarchi F.; Levy J.; Tiberghien A.; Masterson L.; D'Hooge F.; Adams L.; Williams D.; Howard P.; Hartley J., Pre-Clinical Activity of Adct-301, a novel pyrrolobenzodiazepine (PBD) dimer-containing antibody drug conjugate (ADC) targeting CD25-expressing hematological malignancies. In *56th ASH Annual Meeting and Exposition*, San Francisco, 2014; p 4491.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60